Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $18.0852W HIGH $51.60
Volume
88.97 K
Value Traded
23.18 M
Short % Float
8.34%
+4.5%Week
-2.44%1 Month
-19.68%3 Month
+35.61%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.07 B
EPS (TTM)
0.82
P/E Ratio
45.47
Ent. Value
2.61 B
Total Shares
55.71 M
Float Shares
39.25 M
Insiders
20.88%
Institutions
65.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ASTH Catalyst Timeline
Dated clinical, regulatory and corporate events for Astrana Health Inc. Common Stock
Past FDA Catalysts and PDUFA Decisions
How ASTH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Astrana Health Inc. is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ASTH program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Schmidt DavidDirector | Option | 20,000 56,019 held | $5.00 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ASTH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ASTH for Q2 2026. | ||||
ASTH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ASTH ranks across every disease it competes in
Competitive Position is a premium feature
See how ASTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialASTH News
-ASTH
Oct 7, 2026▲ +0.3%today
Alignment Health Expands to Three New California Counties and Adds Hoag and Astrana Health for 2027
Alignment Health Plan is expanding its services into Kern, Kings, and Tulare counties for 2027, increasing its reach to 25 counties in California. The company is adding Hoag and Astrana Health to its provider network, offering a range of Medicare Advantage plans, including options with $0 premiums. This expansion aims to improve access to high-quality, coordinated care for seniors.
Read more →-ASTH
Aug 6, 2026Astrana Health, Inc. Reports Second Quarter 2026 Results
Astrana Health, Inc. reported strong financial results for Q2 2026, with a 49% increase in revenue to $972.5 million and an 81% rise in net income to $18.5 million. The company also achieved an adjusted EBITDA of $68.9 million, up 43% year-over-year. Astrana's performance reflects the effectiveness of its AI-native healthcare platform and its strategic investments in growth opportunities. The company plans to host a conference call to discuss these results further.
Read more →-ASTH
Jul 14, 2026Astrana Health, Inc. Schedules 2026 Second Quarter Financial Results Release and Conference Call
Astrana Health, Inc. has announced the release of its financial results for the second quarter of 2026, scheduled for August 6, 2026. The company will hold a conference call to discuss these results at 2:30 p.m. PT/5:30 p.m. ET. Astrana focuses on empowering healthcare providers through technology to enhance patient care.
Read more →-ASTH
Jul 13, 2026Astrana Health Strengthens Leadership Team to Accelerate Long-Term Growth
Astrana Health has appointed Daniel Rothman as President of Physician Enterprise and Vishal Gupta as Senior Vice President of Enterprise Transformation. These appointments aim to strengthen the leadership team as the company focuses on scaling its AI-enabled healthcare platform. Both leaders bring extensive experience in healthcare operations and finance, which will support Astrana's long-term growth strategy.
Read more →-ASTH
Jul 13, 2026Astrana Health ACOs Deliver $120.4 Million in Gross Shared Savings in 2024 Performance Year
Astrana Health announced that its eight Accountable Care Organizations (ACOs) generated $120.4 million in gross shared savings during the 2024 performance year. All ACOs achieved shared savings, highlighting the effectiveness of Astrana's physician-centric, technology-enabled healthcare model. The company continues to expand its AI-enabled platform, supporting a growing number of providers and patients in value-based care arrangements.
Read more →-ASTH
Jun 4, 2026Astrana Health Named to the 2026 Fortune 1000 List Following Strong Revenue Growth
Astrana Health, Inc. has been named to the Fortune 1000 list for 2026, marking its first appearance on this prestigious ranking. The company reported a revenue of $3.18 billion in fiscal year 2025, reflecting a 56% increase from the previous year. Astrana's growth is attributed to its AI-powered healthcare infrastructure and commitment to value-based care, supporting over 20,000 providers and 1.55 million patients.
Read more →-ASTH
May 12, 2026Astrana Health, Inc. Announces Appointment of Interim National Medical Director
Astrana Health, Inc. has appointed Dr. George Christides as Interim National Medical Director. Dr. Christides brings over 20 years of experience in healthcare leadership, focusing on population health and value-based care. His role will involve leading initiatives across the company's national platform to enhance care management and navigation.
Read more →-ASTH
May 12, 2026M e d i c a r e M e d i c a i d C o m m e r c i al O th e r T h i r d P a r t i es F u l l - r i s k P art i a l - r i sk F u l l - r i s k P art i a l - r i sk C a p i t at i o n , n e t R i s k P o o l S et t l e m e n
The article discusses various financial and operational aspects of AstraZeneca's strategies with Medicare and Medicaid. It highlights their risk management approaches, including full-risk and partial-risk models along with incentive management. However, it primarily focuses on cost management and operational metrics, indicating potential challenges. The projected financial outlook for the coming years appears uncertain due to high general and administrative expenses.
Read more →-ASTH
May 11, 2026Physician Association of California and Astrana Health Launch Collaboration to Strengthen Independent Primary Care
The Physician Association of California and Astrana Health have announced a collaboration to support independent primary care physicians. This partnership aims to simplify healthcare delivery through an AI-powered platform, enhancing care coordination and reducing administrative burdens. PAC physicians will benefit from improved patient engagement and performance insights, ultimately aiming to improve outcomes for Medicare beneficiaries.
Read more →-ASTH
May 7, 2026Astrana Health, Inc. Reports First Quarter
Astrana Health, Inc. reported its financial results for the first quarter of 2026, showcasing significant growth across various sectors. The company achieved total revenues of $965.1 million, marking increases of 51% in Care Partners and 155% in Care Delivery compared to the previous year. President Brandon Sim expressed confidence in Astrana's AI-driven healthcare platform, which aims to improve patient outcomes and operational efficiency. The company also provided guidance for future revenue and adjusted EBITDA, reinforcing its positive financial trajectory.
Read more →-ASTH
Apr 21, 2026Astrana Health, Inc. Schedules 2026 First Quarter Financial Results Release and Conference Call
Astrana Health, Inc. has announced the release of its financial results for Q1 2026, scheduled for May 7, 2026. The company will hold a conference call at 2:30 p.m. PT to discuss these results. A slide presentation will be available on their website, and a recording of the call will be accessible afterward.
Read more →-ASTH
Apr 10, 2026Astrana Health, Inc. to Participate in Upcoming Investor Conferences
Astrana Health, Inc. announced its participation in several upcoming investor conferences, including the Needham Virtual Healthcare Conference and the Bank of America Global Healthcare Conference. The company's leadership will engage in discussions about their technology-enabled healthcare model. Astrana is committed to improving patient outcomes and provider experiences through its innovative care delivery infrastructure.
Read more →-ASTH
Mar 30, 2026PHP Holdings, LLC & Rhode Island Market Condensed Combined and Consolidated Financial Statements (Unaudited) As of
PHP Holdings, LLC and Rhode Island Market released their unaudited combined and consolidated financial statements, showing a net loss of $38,690 for the nine months ended June 30, 2025. The accumulated deficit rose significantly, reaching $1,439,250. Additionally, the total liabilities have increased to $1,569,938, which signals financial challenges for the company. The statements also detail changes in current assets and liabilities, operating revenues, and costs of revenues, providing a snapshot of their financial health.
Read more →-ASTH
Mar 4, 2026Investor Presentation March 2026 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securi
The investor presentation from Astrana discusses forward-looking statements related to the company's business, financial outlook, and operations. It emphasizes future plans for expansion and integration of acquisitions while acknowledging risks and uncertainties that may affect actual outcomes. Furthermore, the presentation highlights non-GAAP financial measures, indicating efforts to provide investors with insight into the company's operational performance. Notably, Astrana aims to improve healthcare accessibility and quality through their coordinated care delivery model, although they recognize challenges in providing cost-effective solutions.
Read more →-ASTH
Mar 2, 2026▲ +29.5%on this newsshared move
Astrana Health, Inc. Reports Fourth Quarter and Year End 2025 Results
Astrana Health, Inc. has reported significant financial results for the fourth quarter and year-end of 2025, with total revenue growing by 56% to $3,181.8 million. The company also noted an adjusted EBITDA of $205.4 million, reflecting its strong operational performance. However, it acknowledged a material weakness in internal control which has led to a delay in filing its annual Form 10-K. Despite this issue, Astrana remains optimistic about achieving further growth in 2026.
Read more →-ASTH
Jan 27, 2026▼ -21.1%on this news
Astrana Health, Inc. Schedules 2025 Fourth Quarter and Year-End Financial Results Release and Conference Call
Astrana Health, Inc. has announced the release of its financial results for the fourth quarter and year ending December 31, 2025. The results will be disclosed before the stock market opens on March 2, 2026, followed by a conference call at 5:30 a.m. PT. The call will also be accessible via webcast, with a slide presentation available on the company's website.
Read more →-ASTH
Jan 12, 2026Investor Presentation January 2026 2 Forward Looking Statements This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Secur
Astrana Health provided a detailed outlook for fiscal year 2025, projecting a significant increase in total revenue to between $3,100 million and $3,180 million. Their adjusted EBITDA is expected to rise to between $200 million and $210 million, reflecting strong performance in various business segments. However, the company also acknowledged transaction costs and other legal matters that could pose risks to achieving these financial goals. Furthermore, the forward-looking statements emphasize uncertainties that could impact actual results.
Read more →-ASTH
Nov 6, 2025Astrana Health, Inc. Reports Third Quarter 2025 Results Company to Host Conference Call on Thursday
Astrana Health, Inc. reported its third quarter 2025 financial results, highlighting solid performance and integration progress with Prospect Health. The company announced strategic partnerships aimed at improving healthcare access and patient outcomes. With total revenues reaching approximately $956 million, Astrana is optimistic about its future, projecting a total revenue guidance of $3.1 billion to $3.18 billion for the year ending December 31, 2025. A conference call to discuss these results will be hosted on November 6, 2025.
Read more →-ASTH
Aug 7, 2025Astrana Health, Inc. Reports Second Quarter 2025 Results Company to Host Conference Call on Thursday
Astrana Health, Inc. announced its financial results for the second quarter ended June 30, 2025, reporting consolidated revenues of $654.8 million, a 36% increase compared to the previous year. The company's CEO highlighted the strength of their technology-driven model in delivering healthcare. Looking ahead, Astrana provided guidance for Q3 and full-year 2025, indicating expected total revenues between $3.1 billion and $3.3 billion. A conference call is scheduled for August 7, 2025, to discuss these results further.
Read more →-ASTH
Jul 2, 2025Astrana Health Announces Closing of Prospect Health Acquisition
Astrana Health has announced the successful closing of its acquisition of Prospect Health, a value-based care delivery network. This acquisition is expected to enhance Astrana's ability to provide patient-centered care and contribute significantly to its revenue and EBITDA. With a network of over 11,000 providers, Prospect Health will enable Astrana to support approximately 600,000 members across different healthcare plans. Additionally, the updated purchase price reflects a cautious approach to capital deployment as the company aims to reduce its net leverage ratio over the next year and a half.
Read more →About Astrana Health Inc. Common Stock
Headquarters1668 S. GARFIELD AVENUE, ALHAMBRA, CA, 91801
BIOPHARMAWATCH ELITE PLUS
Trade the next ASTH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime